Rocket Lab's Neutron Clock Is Ticking — and the Market Is Getting Impatient

Rocket Lab shares fall 18% below 50-day average despite record backlog and revenue, as Neutron delays, insider sales, and SpaceX IPO pressure weigh.

For a company with a record backlog and a launch cadence that rivals its larger competitors, Rocket Lab's share price is telling a very different story. The stock closed Friday at €55.60, down 4.1 percent on the day and roughly 18 percent below its 50-day moving average of €67.82. Since the start of the year, the equity has shed nearly ten percent — a slide that has little to do with operational execution and everything to do with the market's growing unease over what comes next.

The Neutron question hangs over everything

Chief executive Peter Beck sought to reassure investors last week that the Neutron launch pad remains on track for delivery in the fourth quarter of 2026, but he conceded that the window for a first flight before year-end is narrowing. That admission cuts to the heart of the bull case: Rocket Lab's valuation is built on the transition from a small-satellite launch provider to a heavy-lift player, and every delay chips away at that narrative.

The stakes were spelled out by chief financial officer Adam Spice. A successful Neutron test flight, he said, would put Rocket Lab in position to post positive adjusted operating income as soon as the following quarter — a milestone for a company that has been defined by heavy growth investment. Progress on the reusable "Hungry Hippo" payload fairing has been reported, but the tank issue that pushed the first flight into Q4 remains a lingering concern.

Insider selling adds a sour note

The timing of insider transactions has done little to calm nerves. Chief operating officer Frank Klein sold 35,558 shares on August 27 at a weighted average price of $66.61, netting roughly $2.4 million under a Rule 10b5-1 trading plan. That followed a disposal of 45,692 shares on August 24 for approximately $3.18 million. Spice also filed a notice of changes in beneficial ownership.

Klein still holds 925,737 shares after the sales, which softens the signal somewhat. And 10b5-1 plans are, by design, pre-scheduled and legally compliant. But when insider sales cluster alongside a stock trading well below its 50-day average of $67.18 and its 200-day average of $69.43, the optics are hard to dismiss — even if the transactions are procedurally unremarkable.

The real headwind is a rival's IPO

The more significant pressure on the share price may have nothing to do with Rocket Lab at all. The announcement of a SpaceX initial public offering on June 11 has triggered what analysts describe as capital rotation — investors opting for direct exposure to the industry's dominant player rather than a smaller challenger. That explanation aligns with the roughly ten percent decline since the announcement, even as the underlying business has delivered.

The second quarter of 2026 brought record revenue of $234 million and a backlog that has climbed to $2.36 billion, with more than $1 billion in new contracts signed during the quarter alone. The third-quarter revenue outlook of $250 million to $265 million suggests momentum is holding.

Regulatory clouds over the Iridium deal

Adding to the uncertainty is a formal complaint filed by SpaceX with the US Federal Communications Commission regarding Rocket Lab's proposed $8 billion acquisition of Iridium Communications. SpaceX has alleged anticompetitive behavior by Iridium, and while the outcome remains unclear, the regulatory overhang is another reason for investors to sit on their hands.

The core business keeps humming

Amid the noise, the Electron program continues to deliver. The 93rd Electron mission launched successfully on August 20 for Japanese customer iQPS, carrying another QPS-SAR satellite — the 14th launch of 2026. Nine additional iQPS missions are booked through 2030. The company's 15th mission of the year, "Owl Around the World," was scheduled for the day the primary article was published.

Government work is also stacking up. In early August, Rocket Lab secured a $397 million US Space Force contract for the design, launch, and operation of flatellite spacecraft under the SB-AMTI threat-tracking program. Days later, the company joined the Space Force's NITE-STAR-IDIQ framework agreement, a vehicle worth up to $981 million for future space test and training infrastructure work. Last week brought two delivery orders totaling $12 million following Rocket Lab's entry into the Space Data Network Consortium.

Where that leaves investors

The consensus among the 18 analysts covering the stock, as of August 19, stands at a price target of $113 with a "Moderate Buy" rating — well above current levels, though that view predates the latest headwinds. The fundamental case for Rocket Lab remains intact: record backlog, reliable launch cadence, and a clear path to profitability if Neutron performs. But the market is currently pricing in execution risk, and the combination of the SpaceX IPO effect, the Iridium regulatory fight, and insider selling has created a discount that will only close if the company hits its fourth-quarter Neutron window and clears the regulatory path for the Iridium deal.